The MHRA’s new patient-involvement plan links a wider invitation to participate with a harder accountability question: how did people’s contributions influence regulatory work? Published on 5 November, the UK regulator’s plan describes earlier involvement, broader representation and clearer feedback about what changed. These are commitments for delivery, rather than results already demonstrated. MHRA’s announcement
For healthcare organisations and patient groups, separating participation from influence makes the plan easier to assess as it develops.
Lived experience enters more than one kind of decision
The announcement places patient experience across medicines benefit-risk assessment, safety reviews, patient information and future approaches to devices and AI. It also describes work with NICE to reduce duplicated patient-involvement evidence across regulatory and health-technology assessments. That proposed alignment does not itself combine the two organisations’ decisions. The plan’s announced scope
The full plan describes patient experience informing decisions alongside clinical and scientific evidence. It also promises clarity about the purpose, scope and limits of participation. An invitation to contribute therefore needs an explanation of what can be influenced; it is not a promise that every contributor’s preferred outcome will follow. The plan’s principles
Measures come before an impact claim
The document presents a sequence across three delivery years:
- Year 1: develop a proposed measurement and monitoring framework covering participation, diversity and evidence of influence.
- Year 2: establish baseline measures and routine monitoring and reporting.
- Year 3: evaluate impact and outcomes, using the findings to refine the approach.
The People and Public Engagement Committee will review the plan and progress. The plan names these phases Year 1 to Year 3, without assigning each a calendar deadline. Delivery and oversight
This sequence provides different evidence at each stage. Publishing a framework would establish how the agency proposes to measure influence. A later report showing how contributions affected work would answer a further question.
An existing participation route has specific limits
The Patient and Public Community predates this plan. MHRA’s current participation guidance describes individual and voluntary/community-organisation membership, with expectations around meetings, confidentiality and contributing lived experience.
The guidance excludes applications from people living overseas and professionals currently working in healthcare, social care, public health, or the listed medicines, device and technology development/manufacturing industries. Those restrictions concern this community’s membership; they should not be generalized into a ban on all professional input to regulation. Current membership guidance
The next useful reporting milestone is the promised evidence of influence: who was reached, what they contributed and how the agency’s work responded. That is a distinct question from the regulatory reforms covered in our account of the 44 healthcare AI recommendations.
